SCHEMBL13006167

SCHEMBL13006167

COC(=O)/C=[N+](\[O-])Cc1cccc(-c2ccc(C(=O)N(C)C)cc2)c1OCc1ccc(OC)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.39
SLC2A1 P11166 3/20 0.38
FFAR1 O14842 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
CYP1A2 P05177 3/20 0.37
CYP3A4 P08684 3/20 0.37
CYP2D6 P10635 2/20 0.37
HSD17B10 Q99714 2/20 0.37
CYP2C19 P33261 2/20 0.37
MAPK1 P28482 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
TSHR P16473 2/20 0.37
ALOX15 P16050 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
ALDH1A1 P00352 2/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13006176 0.87 CYP1A2 (0.40) CYP1A2CYP3A4CYP2D6HSD17B10CYP2C19
SCHEMBL13060854 0.83 NPC1 (0.46) NPC1SLC2A1FFAR1FFAR4CYP1A2
SCHEMBL13006165 0.82 CYP1A2 (0.45) NPC1FFAR1FFAR4CYP1A2CYP3A4
SCHEMBL13005468 0.80 NPC1 (0.43) NPC1SLC2A1FFAR1FFAR4CYP1A2
SCHEMBL10209695 0.80 TLR4 (0.40) NPC1FFAR1TDP1ALDH1A1MAPT
SCHEMBL13006162 0.78 ERN1 (0.43) NPC1SLC2A1FFAR1FFAR4MEN1
SCHEMBL10266060 0.70 SMPD1 (0.41) NPC1FFAR1TDP1ALDH1A1MAPT
SCHEMBL14970090 0.69 SMPD1 (0.40) NPC1FFAR1TDP1ALDH1A1MAPT
SCHEMBL13006175 0.66 CYP1A2 (0.47) CYP1A2CYP3A4CYP2D6HSD17B10CYP2C19
SCHEMBL1659309 0.63 HPGD (0.73) CYP1A2CYP3A4CYP2C19ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851637-B2 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners INFINITY PHARMACEUTICALS, INC. (US) 2010-12-14 US disclosed